Latest Articles

Two biotechnology companies with a combined valuation exceeding $11 billion have treated zero patients between them. Meanwhile, a third company valued at just $200 million has treated more than 1,000 patients over seven years, with zero serious adverse events reported. This is not a hypothetical scenario. It’s the current state…